Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 1

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 1
---
 | 48 |
| Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information |     | 53 |
| Non-Employee Director Compensation                                                                                                  |     | 54 |
| Security Ownership of Certain Beneficial Owners andManagement                                                                       |     | 56 |
| Securities Authorized for Issuance under Equity Compensation Plans                                                                  |     | 59 |
| Equity Compensation Plan Information                                                                                                |     | 59 |
| 2020 Inducement Plan                                                                                                                |     | 60 |
| Transactions With Related Persons andIndemnification                                                                                |     | 61 |
| Investors’ Rights Agreement                                                                                                         |     | 61 |
| Indemnification Agreements                                                                                                          |     | 61 |
| Policies and Procedures for Transactions with RelatedPersons                                                                        |     | 61 |
| Delinquent Section 16(a) Reports                                                                                                    |     | 62 |
| Other Information for Stockholders                                                                                                  |     | 63 |
| Stockholder Proposals for the 2026 Annual Meeting ofStockholders                                                                    |     | 63 |
| Householding of Proxy Materials                                                                                                     |     | 64 |
| Additional Filings                                                                                                                  |     | 64 |
| Other Matters                                                                                                                       |     | 65 |

#### 2Mirum Pharmaceuticals2025 Proxy Statement

### TABLE OF CONTENTS

#### Mirum Pharmaceuticals, Inc.

#### 989 East Hillsdale Boulevard, Suite 300

#### Foster City, California 94404
<div align='center'>Proxy Statement
for the 2025 Annual Meeting of Stockholders

to be held on May 29, 2025</div>

| Proposals 
 1         
 2         |     | Elect the Board’s three Class III nominees for director named herein to hold office until the Company’s 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal (“Director Election Proposal”) 
 Ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 (“Auditor Ratification Proposal”)                                        |     | Page 
   10 
   27 |     | Board Recommendation |     | FOReach of the Board’s nominees for director 
 FOR                                          |
|:----------|:----|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|-----:|:----|:---------------------|